

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-346US

In Re Application Of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/550,173	9/21/2005	Unknown	26815	Unknown	5227

Title: **PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-346US

In Re Application of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/550,173	9/21/2005	Unknown	26815	Unknown	5227

Title: **PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**


Signature

Dated: **December 1, 2006**

George E. Heibel, Esq.
Reg. No. 42,648

Customer No. 26815

CC:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-346US	Serial No.: 10/550,173
	Applicants: KUMAR <i>et al.</i>	
	Filed: 9/21/2005	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,895,841	1/23/1990	Sugimoto <i>et al.</i>	514	212	
	A2	5,606,064	2/25/1997	Lensky	546	185	
	A3	6,252,081	6/26/2001	Imura	546	206	
	A4	6,413,861	7/2/2002	Huang <i>et al.</i>	438	682	
	A5	6,413,986	7/2/2002	Kosley, Jr. <i>et al.</i>	514	319	
	A6	6,649,765	11/18/2003	Vidyadhar <i>et al.</i>	546	185	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 1 086 706	3/28/2001	EPO	A61K	47/12	
	B2	WO 97/22584	6/26/1997	PCT	C07D	211/32	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C1	Sugimoto et al, "Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds", <i>Journal of Medicinal Chemistry</i> , 38(24):4821-4829 (1995)	
C2	Clark et al., "Quaternary Salts of E2020 Analogues as Acetylcholinesterase Inhibitors for the Reversal of Neuromuscular Block", <i>Bioorganic and Medicinal Chemistry Letters</i> , 12:2565-2568 (2002)	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	